Blocking type i interferon signaling rescues lymphocytes from oxidative stress, exhaustion, and apoptosis in a streptozotocin-induced mouse model of type i diabetes

Oxidative Medicine and Cellular Longevity

Volumn , Issue , 2013, Pages

  Ibrahim, Hany M ^a   El Elaimy, Ibrahim A ^a   Saad Eldien, Heba M ^b   Badr, Badr Mohamed ^a   Rabah, Danny M ^c,d   Badr, Gamal ^d,e  

^a Menoufia University   (Egypt)

^b Assiut University Faculty of Medicine   (Egypt)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

^e Assiut University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MALONDIALDEHYDE; PRO-INFLAMMATORY CYTOKINES; REACTIVE OXYGEN SPECIES; TYPE 1 DIABETES MELLITUS; TYPE I DIABETES; TYPE I INTERFERONS;

CELL DEATH; CELL PROLIFERATION; IMMUNE SYSTEM; LYMPHOCYTES; PHOSPHORYLATION; SIGNALING;

MAMMALS;

GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUCOSE; HYDROPEROXIDE; I KAPPA B ALPHA; INSULIN; INTERFERON; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; MALONALDEHYDE; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; STAT1 PROTEIN; STAT2 PROTEIN; ALPHA BETA INTERFERON RECEPTOR; CYTOKINE; I KAPPA B; IFNAR1 PROTEIN, MOUSE; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; PDCD1 PROTEIN, MOUSE; PROGRAMMED DEATH 1 RECEPTOR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; EXHAUSTION; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; UPREGULATION; ANIMAL; BLOOD; CELL PROLIFERATION; CYTOLOGY; DISEASE MODEL; DRUG ANTAGONISM; EXPERIMENTAL DIABETES MELLITUS; IMMUNOLOGY; METABOLISM; PATHOLOGY;

MUS;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; I-KAPPA B PROTEINS; INTERFERON TYPE I; LYMPHOCYTES; MALONDIALDEHYDE; MICE; OXIDATIVE STRESS; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; RECEPTOR, INTERFERON ALPHA-BETA; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT2 TRANSCRIPTION FACTOR;

EID: 84875491749     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2013/148725     Document Type: Article

References (49)

1. Maahs D. M., Rewers M., Mortality and renal disease in type 1 diabetes mellitus-progress made, more to be done. Journal of Clinical Endocrinology and Metabolism 2006 91 10 3757 3759 2-s2.0-33749545733 10.1210/jc.2006-1730 (Pubitemid 44536838)
2. Thomas H. E., Kay T. W. H., Beta cell destruction in the development of autoimmune diabetes in the non-obese diabetic (NOD) mouse. Diabetes/Metabolism Research and Reviews 2000 16 4 251 261 10.1002/1520-7560(200007/08)16:4<251:: AID-DMRR126>3.0.CO;2-C (Pubitemid 30611785)
3. Beyan H., Buckley L. R., Yousaf N., Londei M., Leslie R. D. G., A role for innate immunity in type 1 diabetes? Diabetes/Metabolism Research and Reviews 2003 19 2 89 100 2-s2.0-0037359445 10.1002/dmrr.341 (Pubitemid 36417193)
4. Lyons T. J., Oxidized low density lipoproteins: a role in the pathogenesis of atherosclerosis in diabetes? Diabetic Medicine 1991 8 5 411 419 2-s2.0-0025758118
5. Baynes J. W., Role of oxidative stress in development of complications in diabetes. Diabetes 1991 40 4 405 412
6. Jain S. K., Hyperglycemia can cause membrane lipid peroxidation and osmotic fragility in human red blood cells. Journal of Biological Chemistry 1989 264 35 21340 21345 (Pubitemid 20017957)
7. Orhan H., Sahin G., Erythrocyte glutathione S-transferase activity in diabetes mellitus: the effect of the treatment. Fabad Journal of Pharmaceutical Sciences 1999 24 3 127 131 2-s2.0-0032804334
8. Sato Y., Hotta N., Sakamoto N., Lipid peroxide level in plasma of diabetic patients. Biochemical Medicine 1979 21 1 104 107 2-s2.0-0018755771 (Pubitemid 9190794)
9. Kaji H., Kurasaki M., Ito K., Increased lipoperoxide value and glutathione peroxidase activity in blood plasma of type 2 (non-insulin- dependent) diabetic women. Klinische Wochenschrift 1985 63 16 765 768 2-s2.0-0021930343 (Pubitemid 15243538)
10. Wang Z., Gleichmann H., GLUT2 in pancreatic islets: crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice. Diabetes 1998 47 1 50 56 2-s2.0-0031963919 (Pubitemid 28030807)
11. Brosky G., Logothetopoulos J., Streptozotocin diabetes in the mouse and guinea pig. Diabetes 1969 18 9 606 611 2-s2.0-0014572551
12. Badr G., Badr B. M., Mahmoud M. H., Mohany M., Rabah D. M., Garraud O., Treatment of diabetic mice with undenatured whey protein accelerates the wound healing process by enhancing the expression of MIP-1 α MIP-2, KC, CX3CL1 and TGF- β in wounded tissue. BMC Immunology 2012 13, article 32
13. Badr G., Supplementation with undenatured whey protein during diabetes mellitus improves the healing and closure of diabetic wounds through the rescue of functional long-lived wound macrophages. Cellular Physiology and Biochemistry 2012 29 3-4 571 582
14. Liadis N., Murakami K., Eweida M., Elford A. R., Sheu L., Gaisano H. Y., Hakem R., Ohashi P. S., Woo M., Caspase-3-dependent β -cell apoptosis in the initiation of autoimmune diabetes mellitus. Molecular and Cellular Biology 2005 25 9 3620 3629 2-s2.0-17644379373 10.1128/MCB.25.9.3620-3629.2005 (Pubitemid 40559568)
15. Lin M., Yin N., Murphy B., Medof M. E., Segerer S., Heeger P. S., Schröppel B., Immune cell-derived C3 is required for autoimmune diabetes induced by multiple low doses of streptozotocin. Diabetes 2010 59 2247 2252
16. Pestka S., Krause C. D., Walter M. R., Interferons, interferon-like cytokines, and their receptors. Immunological Reviews 2004 202 8 32 2-s2.0-9644262469 10.1111/j.0105-2896.2004.00204.x (Pubitemid 39576902)
17. Kerr J. F., Wyllie A. H., Currie A. R., Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. British Journal of Cancer 1972 26 4 239 257 2-s2.0-0015383455
18. Theofilopoulos A. N., Baccala R., Beutler B., Kono D. H., Type I interferons (α / β) in immunity and autoimmunity. Annual Review of Immunology 2005 23 307 336 2-s2.0-17644402442 10.1146/annurev.immunol.23.021704. 115843 (Pubitemid 40563172)
19. Huang X., Yuan J., Goddard A., Foulis A., James R. F. L., Lernmark A., Pujol- Borrell R., Rabinovitch A., Somoza N., Stewart T. A., Interferon expression in the pancreases of patients with type I diabetes. Diabetes 1995 44 6 658 664 2-s2.0-0029036567
20. Fabris P., Floreani A., Tositti G., Vergani D., De Lalla F., Betterle C., Review article: type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Alimentary Pharmacology and Therapeutics 2003 18 6 549 558 2-s2.0-0141650564 10.1046/j.1365-2036.2003.01681.x (Pubitemid 37186604)
21. Stewart T. A., Hultgren B., Huang X., Pitts-Meek S., Hully J., MacLachlan N. J., Induction of type I diabetes by interferon- α in transgenic mice. Science 1993 260 5116 1942 1946 2-s2.0-0027337691 (Pubitemid 23258275)
22. Nakazawa T., Satoh J., Takahashi K., Sakata Y., Ikehata F., Takizawa Y., Bando S. I., Housai T., Li Y., Chen C., Masuda T., Kure S., Kato I., Takasawa S., Taniguchi T., Okamoto H., Toyota T., Complete suppression of insulitis and diabetes in NOD mice lacking interferon regulatory factor-1. Journal of Autoimmunity 2001 17 2 119 125 2-s2.0-0035444577 10.1006/jaut.2001.0531 (Pubitemid 32928207)
23. Otton R., Mendonca J. R., Curi R., Diabetes causes marked changes in lymphocyte metabolism. Journal of Endocrinology 2002 174 55 61 (Pubitemid 34830932)
24. Shidham V. B., Swami V. K., Evaluation of apoptic leukocytes in peripheral blood smears. Archives of Pathology and Laboratory Medicine 2000 124 9 1291 1294 2-s2.0-0033624183
25. Tanaka-Kataoka M., Kunikata T., Takayama S., Iwaki K., Fujii M., Ohashi K., Ikeda M., Kurimoto M., Oral use of interferon- α delays the onset of insulin-dependent diabetes mellitus in nonobese diabetes mice. Journal of Interferon and Cytokine Research 1999 19 8 877 879 2-s2.0-0032858711 10.1089/107999099313398 (Pubitemid 29406641)
26. Saad Eldien H. M., El-Elaimy I. A., Ibrahim H. M., Badr B. M., Badr G., Increased level of Type I Interferon (IFN) during Type I diabetes (T1D) induces apoptosis in spleen-homing T cells. African Journal of Pharmacy and Pharmacology 2012 6 37 2675 2681
27. Badr G., Waly H., Saad Eldien H. M., Abdel-Tawab H., Hassan K., Alhazza I. M., Ebaid H., Alwasel S. H., Blocking type i interferon (IFN) signaling impairs antigen responsiveness of circulating lymphocytes and alters their homing to lymphoid organs: protective role of type i IFN. Cellular Physiology and Biochemistry 2010 26 6 1029 1040 10.1159/000323978
28. Badr G., Saad H., Waly H., Hassan K., Abdel-Tawab H., Alhazza I. M., Ahmed E. A., Type I interferon (IFN-alpha/beta) rescues B-lymphocytes from apoptosis via PI3Kdelta/Akt, Rho-A, NFkappaB and Bcl-2/Bcl(XL). Cellular Immunology 2010 263 31 31 40
29. Baldeon M. E., Chun T., Gaskins H. R., Interferon-alpha and interferon-gamma differentially affect pancreatic beta-cell phenotype and function. American Journal of Physiology 1998 275 1 25 32
30. Whitacre C. M., Cathcart M. K., Oxygen free radical generation and regulation of proliferative activity of human mononuclear cells responding to different mitogens. Cellular Immunology 1992 144 2 287 295 2-s2.0-0026479092 10.1016/0008-8749(92)90245-K
31. Baynes J. W., Role of oxidative stress in the development of complications in diabetes. Diabetes 1991 40 405 412
32. Rösen P., Nawroth P. P., King G., Möller W., Tritschler H. J., Packer L., The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a congress series sponsored by UNESCO-MCBN, the American diabetes association and the German diabetes society. Diabetes/Metabolism Research and Reviews 2001 17 3 189 212 2-s2.0-0034939115 10.1002/dmrr.196 (Pubitemid 32624602)
33. Burdon R. H., Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radical Biology and Medicine 1995 18 775 794
34. Rønn S. G., Billestrup N., Mandrup-Poulsen T., Diabetes and suppressors of cytokine signaling proteins. Diabetes 2007 56 2 541 548 2-s2.0-33847043503 10.2337/db06-1068
35. Wdrychowicz A., Dziatkowiak H., Sztefko K., Wdrychowicz A., Interleukin-6 (IL-6) and IGF-IGFBP system in children and adolescents with type 1 diabetes mellitus. Experimental and Clinical Endocrinology and Diabetes 2004 112 8 435 439 2-s2.0-4744339468 10.1055/s-2004-821189 (Pubitemid 39311025)
36. Yudkin J. S., Kumari M., Humphries S. E., Mohamed-Ali V., Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000 148 2 209 214 2-s2.0-0033984744 10.1016/S0021-9150(99) 00463-3 (Pubitemid 30064452)
37. Dogan Y., Akarsu S., Ustundag B., Yilmaz E., Gurgoze M. K., Serum IL-1 β IL-2, and IL-6 in insulin-dependent diabetic children. Mediators of Inflammation 2006 2006 6 2-s2.0-33645222743 10.1155/MI/2006/59206 59206
38. Taylor J. L., Grossberg S. E., The effects of interferon-alpha on the production and action of other cytokines. Seminars in Oncology 1998 25 23 29 (Pubitemid 28093152)
39. Masini M., Campani D., Boggi U., Menicagli M., Funel N., Pollera M., Lupi R., Del Guerra S., Bugliani M., Torri S., Del Prato S., Mosca F., Filipponi F., Marchetti P., Hepatitis C virus infection and human pancreatic β -cell dysfunction. Diabetes Care 2005 28 4 940 941 2-s2.0-20144388828 10.2337/diacare.28.4.940 (Pubitemid 40434503)
40. Fallahi P., Ferri C., Ferrari S. M., Corrado A., Sansonno D., Antonelli A., Cytokines and HCV-related disorders. Clinical and Developmental Immunology 2012 2012 10 10.1155/2012/468107 468107
41. Singh L., Arora S. K., Bakshi D. K., Majumdar S., Wig J. D., Potential role of CXCL10 in the induction of cell injury and mitochondrial dysfunction. International Journal of Experimental Pathology 2010 91 3 210 223 2-s2.0-77952695074 10.1111/j.1365-2613.2009.00697.x
42. Means T. K., Latz E., Hayashi F., Murali M. R., Golenbock D. T., Luster A. D., Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. Journal of Clinical Investigation 2005 115 2 407 417 2-s2.0-14944357367 10.1172/JCI200523025 (Pubitemid 40385482)
43. Chawla-Sarkar M., Lindner D. J., Liu Y. F., Williams B. R., Sen G. C., Silverman R. H., Borden E. C., Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003 8 3 237 249 2-s2.0-0037790592 10.1023/A:1023668705040 (Pubitemid 36749609)
44. Nielsen C., Hansen D., Husby S., Jacobsen B. B., Lillevang S. T., Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. Tissue Antigens 2003 62 6 492 497 2-s2.0-0344099132 10.1046/j.1399-0039.2003.00136.x (Pubitemid 37479307)
45. Klenerman P., Hill A., T cells and viral persistence: lessons from diverse infections. Nature Immunology 2005 6 873 879 (Pubitemid 43090441)
46. Chesler D. A., Dodard C., Lee G. Y., Levy D. E., Reiss C. S., Interferon- γ -induced inhibition of neuronal vesicular stomatitis virus infection is STAT1 dependent. Journal of NeuroVirology 2004 10 1 57 63 2-s2.0-1542315427 10.1080/13550280490261707 (Pubitemid 38325110)
47. Lamhamedi-Cherradi S. E., Zheng S., Hilliard B. A., Xu L., Sun J., Alsheadat S., Liou H. C., Chen Y. H., Transcriptional regulation of type I diabetes NF- B. Journal of Immunology 2003 171 9 4886 4892 2-s2.0-0142241399
48. Yang C. H., Murti A., Pfeffer S. R., Kim J. G., Donner D. B., Pfeffer L. M., Interferon alpha /beta promotes cell survival by activating nuclear factor kappa B through phosphatidylinositol 3-kinase and AKT. Journal of Biological Chemistry 2001 276 13756 13761
49. Mitsiades C. S., Mitsiades N., Koutsilieris M., The AKT pathway: molecular targets for anti-cancer drug development. Current Cancer Drug Targets 2004 4 3 235 256 2-s2.0-2342436459 10.2174/1568009043333032 (Pubitemid 38560073)